Devonian Health Group Inc. (TSXV:GSD)
0.1400
0.00 (0.00%)
Jun 27, 2025, 4:00 PM EDT
Devonian Health Group Revenue
Devonian Health Group had revenue of 7.36M CAD in the quarter ending April 30, 2025, with 43.66% growth. This brings the company's revenue in the last twelve months to 31.28M, up 215.07% year-over-year. In the fiscal year ending July 31, 2024, Devonian Health Group had annual revenue of 17.82M with 659.60% growth.
Revenue (ttm)
31.28M
Revenue Growth
+215.07%
P/S Ratio
0.66
Revenue / Employee
4.47M
Employees
8
Market Cap
20.75M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jul 31, 2024 | 17.82M | 15.47M | 659.60% |
Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
Jul 31, 2019 | Pro | Pro | Pro |
Jul 31, 2018 | Pro | Pro | Pro |
Jul 31, 2017 | Pro | Pro | Pro |
Jul 31, 2016 | Pro | Pro | Pro |
Jul 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sienna Senior Living | 896.45M |
Green Thumb Industries | 1.64B |
dentalcorp Holdings | 1.58B |
Extendicare | 1.47B |
Cronos Group | 179.08M |
WELL Health Technologies | 990.34M |
Trulieve Cannabis | 1.71B |
Curaleaf Holdings | 1.89B |
Devonian Health Group News
- 12 days ago - Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy - IBTimes
- 2 months ago - Devonian Health Group Announces Reinstatement of Quotation on the TSXV - Financial Post
- 4 months ago - Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis - Financial Post
- 4 months ago - Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Financial Post
- 5 months ago - Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study - Financial Post